<DOC>
	<DOCNO>NCT01565122</DOCNO>
	<brief_summary>This multi-center , observational study evaluate clinical practice pattern , efficacy safety RoActemra/Actemra ( tocilizumab ) patient rheumatoid arthritis . Data collect eligible patient initiate RoActemra/Actemra treatment treat physician accord approve label 12 month start treatment .</brief_summary>
	<brief_title>An Observational Study Rheumatoid Arthritis Patients Treated With RoActemra/Actemra ( Tocilizumab )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Moderate severe rheumatoid arthritis Patients treat physician make decision commence RoActemra/Actemra treatment . In Group A RoActemra/Actemra prescribe within 8 week prior enrolment visit . In Group B RoActemra/Actemra start 8 week inclusion study , January 2011 RoActemra/Actemra treatment 8 week prior inclusion visit Group A , January 2011 Group B Previous RoActemra/Actemra treatment clinical trial compassionate use Treatment investigational agent within 4 week ( 5 halflives investigational agent , whichever long ) start treatment RoActemra/Actemra History autoimmune disease joint inflammatory disease rheumatoid arthritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>